Elixirgen Therapeutics
Life-changing therapies for rare diseases and aging-associated diseases
United States · Founded 2017 · $4.0M raised
- Founded
- 2017
- Business Model
- B2B
- Website
- elixirgentx.com
- Total Funding
- $4.0M
- Last Round
- $4.0M Series AJul 2018
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Elixirgen Therapeutics develops cell, gene, and mRNA therapies for rare and aging-associated diseases. Its lead ZSCAN4 program is in a Phase I/II trial for telomere biology disorders, while its Bobcat mRNA platform is being developed for diseases involving large genes, including Duchenne muscular dystrophy. The company uses proprietary approaches to address unmet needs in regenerative medicine.
Summary
Elixirgen Therapeutics is a Biotech company based in United States, founded in 2017. It has raised $4.0M in total across 1 round, most recently a $4.0M Series A round in Jul 2018. Investors include University of Tokyo Edge Capital.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jul 2018
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/elixirgen-therapeutics"><img src="https://indexed.vc/api/badge/company/elixirgen-therapeutics" alt="Elixirgen Therapeutics on Indexed.vc" width="260" height="76" /></a>